KEY PREDICTIVE FACTORS OF AXITINIB (AG-013736)-INDUCED PROTEINURIA AND EFFICACY: A JAPANESE PHASE II STUDY IN PATIENTS WITH CYTOKINE-REFRACTORY METASTATIC RENAL CELL CANCER (MRCC)

被引：0
|
作者：
Tomita, Y. [1 ]
Uemura, H. [2 ]
Fujimoto, H. [3 ]
Kanayama, H. [4 ]
Shinohara, N. [5 ]
Nakazawa, H. [6 ]
Ozono, S. [7 ]
Naito, S. [8 ]
Akaza, H. [9 ]
机构：
[1] Yamagata Univ, Sch Med, Yamagata 99023, Japan
[2] Kinki Univ, Sch Med, Osaka 589, Japan
[3] Natl Canc Ctr, Tokyo, Japan
[4] Univ Tokushima, Fac Med, Tokushima 770, Japan
[5] Hokkaido Univ Hosp, Sapporo, Hokkaido 060, Japan
[6] Tokyo Womens Med Univ, Med Ctr E, Tokyo, Japan
[7] Hamamatsu Univ Sch Med, Hamamatsu, Shizuoka 4312102, Japan
[8] Kyushu Univ Hosp, Fukuoka 812, Japan
[9] Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：282 / 282
页数：1
相关论文
共 50 条
  • [31] Multicenter Phase II Trial of S-1 in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
    Naito, Seiji
    Eto, Masatoshi
    Shinohara, Nobuo
    Tomita, Yoshihiko
    Fujisawa, Masato
    Namiki, Mikio
    Nishikido, Masaharu
    Usami, Michiyuki
    Tsukamoto, Taiji
    Akaza, Hideyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (34) : 5022 - 5029
  • [32] A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors
    Sharma, S.
    Abhyankar, V.
    Burgess, R. E.
    Infante, J.
    Trowbridge, R. C.
    Tarazi, J.
    Kim, S.
    Tortorici, M.
    Chen, Y.
    Robles, R. L.
    ANNALS OF ONCOLOGY, 2010, 21 (02) : 297 - 304
  • [33] Sunitinib continuous daily dosing in patients with cytokine-refractory metastatic renal cell carcinoma: Final results of a phase II study
    Roigas, J.
    Peschel, C.
    Escudier, B.
    ONKOLOGIE, 2008, 31 : 179 - 180
  • [34] Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study
    Tomita, Yoshihiko
    Fukasawa, Satoshi
    Oya, Mototsugu
    Uemura, Hirotsugu
    Shinohara, Nobuo
    Habuchi, Tomonori
    Rini, Brian I.
    Chen, Ying
    Bair, Angel H.
    Ozono, Seiichiro
    Naito, Seiji
    Akaza, Hideyuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 46 (11) : 1031 - 1041
  • [35] Phase I/II study of axitinib (axi) and nivolumab (nivo) in patients with metastatic renal cell carcinoma (mRCC).
    Zibelman, Matthew R.
    Geynisman, Daniel M.
    Molina, Ana M.
    Malizzia, Lois
    Devarajan, Karthik
    Luong, Diana
    Sullivan, Elizabeth
    Carducci, Michael Anthony
    Plimack, Elizabeth R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] Phase II study of lenalidomide in patients (pts) with metastatic renal cell cancer (MRCC).
    Marsh, L.
    Khan, M.
    Needle, M.
    Amato, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 224S - 224S
  • [37] Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
    Escudier, Bernard
    Roigas, Jan
    Gillessen, Silke
    Harmenberg, Ulrika
    Srinivas, Sandhya
    Mulder, Sasja F.
    Fountzilas, George
    Peschel, Christian
    Flodgren, Per
    Maneval, Edna Chow
    Chen, Isan
    Vogelzang, Nicholas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : 4068 - 4075
  • [38] A phase I/II study of AG-013736, an oral anti-angiogenesis agent, in combination with docetaxel in patients (pts) with metastatic breast cancer (MBC)
    Rugo, HS
    Stopeck, A
    Badorf, A
    Pithavala, YK
    Steinfeldt, HM
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S62 - S62
  • [39] Phase II study of CC-5013 in patients (pts) with metastatic renal cell cancer (MRCC)
    Rawat, A
    Needle, MN
    Miles, B
    Amato, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 403S - 403S
  • [40] A phase II study of the efficacy and safety of sunitinib in treatment-naive and pretreated Japanese patients (pts) with metastatic renal cell carcinoma (mRCC)
    Uemura, H.
    Shinohara, N.
    Naito, S.
    Akaza, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345